China Universal Asset Management Company’s Royalty Pharma RPRX Stock Holding History

China Universal Asset Management Company’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.76M	Sell	120,547 -9,900	-8%	-$515K	0.4%	50
2026 Q1	$6.26M	Buy	130,447 +50,827	+64%	+$2.23M	0.47%	47
2025 Q4	$3.08M	Buy	79,620 +3,845	+5%	+$147K	0.24%	77
2025 Q3	$2.67M	Sell	75,775 -8,856	-10%	-$321K	0.22%	86
2025 Q2	$3.05M	Sell	84,631 -2,287	-3%	-$75.8K	0.29%	70
2025 Q1	$2.71M	Sell	86,918 -7,290	-8%	-$231K	0.25%	88
2024 Q4	$2.4M	Buy	94,208 +8,018	+9%	+$213K	0.22%	92
2024 Q3	$2.44M	Buy	86,190 +33,206	+63%	+$920K	0.27%	79
2024 Q2	$1.4M	Sell	52,984 -32,895	-38%	-$912K	0.2%	89
2024 Q1	$2.61M	Buy	85,879 +34,207	+66%	+$1.01M	0.33%	65
2023 Q4	$1.45M	Buy	51,672 +40,149	+348%	+$1.1M	0.28%	83
2023 Q3	$313K	Buy	11,523 +5,649	+96%	+$168K	0.09%	122
2023 Q2	$181K	Sell	5,874 -131	-2%	-$4.44K	0.06%	135
2023 Q1	$216K	Buy	6,005 +1,524	+34%	+$56.5K	0.07%	114
2022 Q4	$177K	Buy	4,481 +388	+9%	+$16.2K	0.07%	107
2022 Q3	$164K	Buy	+4,093	New	+$175K	0.07%	99

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

China Universal Asset Management Company's RPRX Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Royalty Pharma (RPRX) stake by 7.6% in Q2 2026, selling an estimated $515K and leaving 120,547 shares worth $6.76M. The position accounts for 0.4% of the portfolio, ranked #50.

China Universal Asset Management Company first reported a position in RPRX in Q3 2022 and has held it in 16 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

China Universal Asset Management Company held 120,547 shares of Royalty Pharma worth $6.76M as of Q2 2026.
China Universal Asset Management Company sold 9,900 Royalty Pharma shares in Q2 2026, an estimated $515K.
Royalty Pharma made up 0.4% of China Universal Asset Management Company's portfolio in Q2 2026, its #50 holding.
China Universal Asset Management Company first reported a position in Royalty Pharma in Q3 2022 and has held it in 16 quarters since.
647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.